Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Ruijin Hospital
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07594899CT.gov AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL | — | Not Yet Recruiting | — | — | — |
NCT07514169CT.gov The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL | — | Recruiting | — | — | — |
NCT06167785CT.gov A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T | — | Recruiting | — | — | — |
NCT06375733CT.gov A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Zanubrutinib (this asset) | Ruijin Hospital | P2 | B · 60 |
| Axicabtagene Ciloleucel | Zhejiang Cancer Hospital | P4 | BB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P4 | BB |
| Fludarabine | M.D. Anderson Cancer Center | P4 | BB |
| Etoposide | University of California, Davis | P2/3 | BB |
| Adriamycin | Ruijin Hospital | P3 | BB |
| Prednisone | Ruijin Hospital | P3 | BB |
| Golcadomide | Allison Winter | P3 | B |
| Surovatamig | AstraZeneca | P3 | B |
+41 more in the Large B-Cell Lymphoma cohort
Other indications for Zanubrutinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 73 |
| Splenic Marginal Zone Lymphoma | — | P3 | BB · 68 |
| Marginal Zone Lymphoma | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Zanubrutinib in Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/zanubrutinib-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →